| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2877224 | The Annals of Thoracic Surgery | 2014 | 8 Pages |
Abstract
A murine model of CRS for malignant mesothelioma allows the in vivo assessment of multimodal therapy, including nanoparticle delivery. Combination therapy was superior to no treatment or CRS alone in prolonging survival. Treatment with Pax-eNP improved overall survival in the setting of CRS, suggesting that Pax-eNP merits further evaluation for intracavitary drug delivery following the surgical resection of malignant mesothelioma.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Morgan D. MD, Kimberly Ann V. PhD, Jacqueline E. BS, Robert F. MD, PhD, Xiaoyin PhD, Mark W. PhD, Yolonda L. MD, PhD,